Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab

 
• By Mandy Jackson

Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.

Lung cancer; wooden puzzle on dark surface
Questions about Lumakras in KRAS G12C-mutated lung cancer with co-mutations may be answered in Phase III • Source: Alamy

More from ASCO

More from Conferences